CRITICAL READING ST HELIER VTS 2008 RCGP Curriculum Core Statement Domain 3 AS.

Slides:



Advertisements
Similar presentations
Appraisal of an RCT using a critical appraisal checklist
Advertisements

How to assess an abstract
How would you explain the smoking paradox. Smokers fair better after an infarction in hospital than non-smokers. This apparently disagrees with the view.
Critical Appraisal: Epidemiology 101 POS Lecture Series April 28, 2004.
K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.
Valsartan Antihypertensive Long-Term Use Evaluation Results
Introduction to Critical Appraisal : Quantitative Research
Critical Appraisal of Systematic Reviews Douglas Newberry.
CRITICAL APPRAISAL Dr. Cristina Ana Stoian Resident Journal Club
Critical Appraisal for MRCGP Jim McMorran Coventry GP GP trainer Editor GPnotebook (
Statistics By Z S Chaudry. Why do I need to know about statistics ? Tested in AKT To understand Journal articles and research papers.
Statistics for Health Care
The Bahrain Branch of the UK Cochrane Centre In Collaboration with Reyada Training & Management Consultancy, Dubai-UAE Cochrane Collaboration and Systematic.
Critical appraisal Systematic Review กิตติพันธุ์ ฤกษ์เกษม ภาควิชาศัลยศาสตร์ มหาวิทยาลัยเชียงใหม่
Multiple Choice Questions for discussion
Critical Reading. Critical Appraisal Definition: assessment of methodological quality If you are deciding whether a paper is worth reading – do so on.
Reading Scientific Papers Shimae Soheilipour
EBD for Dental Staff Seminar 2: Core Critical Appraisal Dominic Hurst evidenced.qm.
DEB BYNUM, MD AUGUST 2010 Evidence Based Medicine: Review of the basics.
Clinical Outcomes with Newer Antihyperglycemic Agents
Lecture 17 (Oct 28,2004)1 Lecture 17: Prevention of bias in RCTs Statistical/analytic issues in RCTs –Measures of effect –Precision/hypothesis testing.
Study design P.Olliaro Nov04. Study designs: observational vs. experimental studies What happened?  Case-control study What’s happening?  Cross-sectional.
EVIDENCE BASED MEDICINE Effectiveness of therapy Ross Lawrenson.
Statistics for nMRCGP Jo Kirkcaldy. Curriculum Condensed Knowledge Incidence and prevalence Specificity and sensitivity Positive and negative predictive.
Evidence Based Medicine Meta-analysis and systematic reviews Ross Lawrenson.
How to Analyze Therapy in the Medical Literature (part 2)
Tissue Plasminogen Activator for Acute Ischemic Stroke National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
Understanding real research 4. Randomised controlled trials.
EBCP. Random vs Systemic error Random error: errors in measurement that lead to measured values being inconsistent when repeated measures are taken. Ie:
Quality Education for a Healthier Scotland Pharmacy Critical Appraisal Skills Basic I NHS Education Scotland Produced in collaboration with the Association.
Clinical Writing for Interventional Cardiologists.
How to read a paper D. Singh-Ranger. Academic viva 2 papers 1 hour to read both Viva on both papers Summary-what is the paper about.
Stats Facts Mark Halloran. Diagnostic Stats Disease present Disease absent TOTALS Test positive aba+b Test negative cdc+d TOTALSa+cb+da+b+c+d.
Critical Reading of Medical Articles
Critical Reading. Critical Appraisal Definition: assessment of methodological quality If you are deciding whether a paper is worth reading – do so on.
Objectives  Identify the key elements of a good randomised controlled study  To clarify the process of meta analysis and developing a systematic review.
P Sever (Co-chair), B Dahlöf (Co-chair), N Poulter (Secretary), H Wedel (Statistician), G Beevers, M Caulfield, R Collins, SE Kjeldsen, A Kristinsson,
1 Pre-Specified Outcomes All primary and secondary outcomes and their components were pre-specified, i.e., they appeared in the protocol, manual of operations.
EVALUATING u After retrieving the literature, you have to evaluate or critically appraise the evidence for its validity and applicability to your patient.
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
CRITICAL APARAISAL OF A PAPER ON THERAPY PROF.JAMAL S.ALJARALLAH.
Biostatistics Board Review Parul Chaudhri, DO Family Medicine Faculty Development Fellow, UPMC St Margaret March 5, 2016.
Critical Appraisal of a Paper Feedback. Critical Appraisal Full Reference –Authors (Surname & Abbreviations) –Year of publication –Full Title –Journal.
CRITICAL APARAISAL OF A PAPER ON THERAPY PROF.JAMAL S.ALJARALLAH 1436(2015)
“Reading and commenting papers” (Scientific English) Alexis Descatha INSERM, UMS UVSQ- Unité de pathologie professionnelle, Garches.
Clinical Outcomes with Newer Antihyperglycemic Agents
HelpDesk Answers Synthesizing the Evidence
Clinical Outcomes with Newer Antihyperglycemic Agents
The SPRINT Research Group
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis  Stavros Stavrakis, MD  The American Journal.
An Idiots Guide to Statistics Curriculum 3.6
Question 1 A new ‘Super test’ claims to have a superb capability to diagnose disease X. Its sensitivity is 99% and specificity is 90%. Which of the following.
EVIDENCE BASED MEDICINE
The Anglo Scandinavian Cardiac Outcomes Trial
PS Sever, PM Rothwell, SC Howard, JE Dobson, B Dahlöf,
Chapter 7 The Hierarchy of Evidence
The following slides highlight a presentation at the Hotline Session of the European Society of Cardiology Annual Congress, September 3-7, 2005 in Stockholm,
NAPLEX preparation: Biostatistics
Systolic Blood Pressure Intervention Trial (SPRINT)
The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.
on behalf of the ASCOT Investigators *Imperial College London, UK
The Hypertension in the Very Elderly Trial (HYVET)
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
ASCOT-BPLA: Primary and secondary end points
Interpreting Basic Statistics
Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.
A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned  Robert E.
How to assess an abstract
Basic statistics.
Presentation transcript:

CRITICAL READING ST HELIER VTS 2008 RCGP Curriculum Core Statement Domain 3 AS

What is expected…. Hierarchy of evidence Statistical terms Data Presentation Seminal trials

What is expected…. Mean, median, mode Normal distribution curve, std deviation ARR, RRR NNT, NNH P value, confidence intervals Sensitivity, specificity PPV, NPV

Critical Reading Critical Appraisal – Look at the specific objectives, methods, and results of the study Critical reflection – Judge and discuss the implications for the world outside the study

Critical Appraisal Title, author, institute, journal Ethics References Conflicts of interests

Critical Appraisal Introduction – Background – Aims – Relevance – Originality Methods – Design – Outcome measures – Subjects

Design Time Frame Prospective Cross-Sectional Retrospective Observational / Interventional Controlled / Uncontrolled Randomised / Non-randomised

Bias Selection Bias – Typical sample? – Exclusions (numbers and reasons) clear? – Same conditions for both groups Measurement Bias – Observer error – Validity – Reliability

Bias Validity – closeness to true measure – Internal – Can I believe the results? – External – If I can, do they apply to the real world? Reliability – repeatability of the measurements

Implications Generalisation Consequences P People and ethics R Resources A Audit protocols and quality T Time and training S Safety and society

Critical Appraisal Presentation Experimental Design Numbers Information Bias Selection Bias

Summarising A Paper General aim – one sentence why the study was done Objective – what was the specific aim of the study? Design Setting – where was the study done?

Summarising a Paper Population Target Sampling frame Study population Methods Intervention Baseline Outcome Results Author’s conclusions – main points

Does treatment work? Consider the DCCT Trial Incidence of Neuropathy is 9.6% in control group(CER) Intervention group (6yrs very tight control) is 2.8%(EER)

Does treatment work? Relative risk reduction is: 9.6%-2.8% 9.6%equals71% Absolute risk reduction is: 9.6% - 2.8%equals6.8%

RRR Same result if 96% got neuropathy in the control group and 28% in intervention group Fails to show baseline risk or size of effect Tiny effect can look impressive

NNT Inverse of ARR 100/6.8%=14.7, i.e. treat 15 patients for 6 years to prevent one extra neuropathy Practical result Easier to compare treatments Beware intention to treat figures

Screening Sensitivity%age with +ve test result High if few missed Specificity%age with true negative result High if few false alarms Predictive valueproportion of +ve results who have condition Depends on prevalence

Odds Ratios Ratio of events in intervention group v control group Forest plot 1 means no effect CI including 1 – no effect Further away from 1, more likely a true effect

PPV and NPV Positive Predictive Value Ability of test to pick out disease – Eg 160 positive results from a diseased population of 200: 160/200 = 80% PPV Negative Predictive Value Ability of test to pick out those who do not have disease – Eg 70 negative results from a healthy population of 100: 70/100 = 70% PPV

Qualititive studies Studying ideas and concepts Narrative based medicine Understanding patient Turns anecdotes into data/observations Passive observation of behaviour Participation Groups One to One interviews Focus Groups Document Studies

Systematic Reviews Does the review examine an important clinical question Was there a substantial effort to search all relevant literature Was methodological quality assessed and trials weighted accordingly How sensitive are the results to the way the review has been done Have the results been interpreted with common sense and due regard to the broader issues

RCT Expensive Time-consuming Small numbers (usually) Subjects and settings limit generalisation of results Random allocation cannot overcome bias – Intention to treat, drop-out rates etc

Audit Systematic survey with a purpose that requires repeating More than a survey as part of process of change – Uncontrolled observational study that may become an uncontrolled prospective interventional study

ASCOT

Summary of all end points The area of the blue square is proportional to the amount of statistical information Amlodipine  perindopril better Atenolol  thiazide better Primary Non-fatal MI (incl silent) + fatal CHD Secondary Non-fatal MI (exc. Silent) +fatal CHD Total coronary end point Total CV event and procedures All-cause mortality Cardiovascular mortality Fatal and non-fatal stroke Fatal and non-fatal heart failure Tertiary Silent MI Unstable angina Chronic stable angina Peripheral arterial disease Life-threatening arrhythmias New-onset diabetes mellitus New-onset renal impairment Post hoc Primary end point + coronary revasc procs CV death + MI + stroke 2.00 Unadjusted Hazard ratio (95% CI) 0.90 ( ) 0.87 ( ) 0.87 ( ) 0.84 ( ) 0.89 ( ) 0.76 ( ) 0.77 ( ) 0.84 ( ) 1.27 ( ) 0.68 ( ) 0.98 ( ) 0.65 ( ) 1.07 ( ) 0.70 ( ) 0.85 ( ) 0.86 ( ) 0.84 ( )

Adverse events leading to treatment discontinuation Adverse event Amlodipine  perindopril (%) Atenolol  thiazide (%) Total2358 (24.5)2402 (25.0) Serious162 (1.7)254 (2.6)* * p<0.0001